Loading
A phase 1 trial of SYNC-T Therapy SV-102 run by Williams Cancer Foundation, completed.
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05544227 by Williams Cancer Foundation, with 15 participants enrolled, started 2023-02-01. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: SV-102.
Shares Syncromune, SYNC-T Therapy SV-102, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/